Carregant...

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

PURPOSE: Dual blockade of HER2 with trastuzumab with lapatinib or with pertuzumab is a superior treatment approach compared to single agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphatidyli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Garrett, Joan T., Sutton, Cammie R., Kuba, María Gabriela, Cook, Rebecca S ., Arteaga, Carlos L.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563762/
https://ncbi.nlm.nih.gov/pubmed/23224399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!